 Yasir Rahmatallah
Concepts (124)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 10 | 2025 | 1099 | 2.120 |
Why?
| | Computational Biology | 4 | 2025 | 209 | 1.720 |
Why?
| | Voice | 2 | 2025 | 30 | 1.090 |
Why?
| | Transcriptome | 3 | 2019 | 357 | 1.080 |
Why?
| | Colonic Neoplasms | 2 | 2019 | 163 | 1.040 |
Why?
| | Parkinson Disease | 2 | 2025 | 168 | 0.940 |
Why?
| | Databases, Genetic | 3 | 2025 | 82 | 0.860 |
Why?
| | RNA | 2 | 2015 | 174 | 0.850 |
Why?
| | Gene Regulatory Networks | 6 | 2019 | 112 | 0.850 |
Why?
| | Proteome | 3 | 2021 | 175 | 0.840 |
Why?
| | Sequence Analysis, RNA | 4 | 2018 | 96 | 0.700 |
Why?
| | Genes, Neoplasm | 1 | 2019 | 31 | 0.620 |
Why?
| | Consensus | 1 | 2019 | 195 | 0.570 |
Why?
| | Renal Insufficiency, Chronic | 4 | 2023 | 198 | 0.560 |
Why?
| | Colonic Polyps | 1 | 2017 | 39 | 0.540 |
Why?
| | Software | 2 | 2017 | 281 | 0.540 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2015 | 178 | 0.510 |
Why?
| | Adenoma | 1 | 2017 | 114 | 0.500 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2025 | 90 | 0.470 |
Why?
| | Genes, X-Linked | 1 | 2014 | 7 | 0.450 |
Why?
| | Signal Transduction | 4 | 2019 | 1724 | 0.420 |
Why?
| | Azospirillum brasilense | 2 | 2022 | 4 | 0.340 |
Why?
| | Thrombosis | 2 | 2023 | 250 | 0.320 |
Why?
| | Phenotype | 3 | 2025 | 792 | 0.320 |
Why?
| | Multivariate Analysis | 3 | 2017 | 601 | 0.290 |
Why?
| | Principal Component Analysis | 2 | 2019 | 53 | 0.290 |
Why?
| | Algorithms | 2 | 2025 | 673 | 0.280 |
Why?
| | Proteomics | 2 | 2021 | 332 | 0.270 |
Why?
| | Humans | 16 | 2025 | 52441 | 0.260 |
Why?
| | Glucocorticoids | 2 | 2019 | 234 | 0.240 |
Why?
| | Sound Spectrography | 1 | 2025 | 14 | 0.230 |
Why?
| | Computer Simulation | 3 | 2017 | 285 | 0.220 |
Why?
| | Cecum | 2 | 2021 | 56 | 0.190 |
Why?
| | Herbaspirillum | 1 | 2022 | 2 | 0.190 |
Why?
| | Gene Expression | 3 | 2022 | 618 | 0.180 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 1429 | 0.170 |
Why?
| | Infant Formula | 1 | 2021 | 154 | 0.160 |
Why?
| | Ruminococcus | 1 | 2019 | 7 | 0.150 |
Why?
| | Starch | 1 | 2019 | 12 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2019 | 116 | 0.150 |
Why?
| | Profilins | 1 | 2018 | 13 | 0.150 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2018 | 36 | 0.140 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2017 | 34 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 336 | 0.140 |
Why?
| | GTP-Binding Proteins | 1 | 2017 | 86 | 0.140 |
Why?
| | Hyperplasia | 1 | 2017 | 96 | 0.140 |
Why?
| | Neurodegenerative Diseases | 1 | 2018 | 83 | 0.130 |
Why?
| | Diet | 1 | 2021 | 591 | 0.130 |
Why?
| | Cluster Analysis | 1 | 2017 | 236 | 0.130 |
Why?
| | Reproducibility of Results | 2 | 2023 | 1223 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2017 | 141 | 0.130 |
Why?
| | Cell Cycle Proteins | 1 | 2017 | 168 | 0.130 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2017 | 132 | 0.130 |
Why?
| | Down-Regulation | 1 | 2017 | 348 | 0.130 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 133 | 0.130 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 152 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2017 | 412 | 0.120 |
Why?
| | Protein Interaction Maps | 1 | 2016 | 28 | 0.120 |
Why?
| | Up-Regulation | 1 | 2017 | 462 | 0.120 |
Why?
| | Protein Interaction Mapping | 1 | 2016 | 39 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 286 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2017 | 181 | 0.120 |
Why?
| | Kidney | 1 | 2020 | 716 | 0.120 |
Why?
| | Bacterial Proteins | 1 | 2019 | 347 | 0.120 |
Why?
| | Sample Size | 1 | 2015 | 50 | 0.120 |
Why?
| | Neoplasm Proteins | 1 | 2017 | 328 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 853 | 0.120 |
Why?
| | Male | 5 | 2025 | 26874 | 0.110 |
Why?
| | DNA Replication | 1 | 2016 | 159 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 224 | 0.110 |
Why?
| | DNA Helicases | 1 | 2016 | 147 | 0.110 |
Why?
| | Lymphocytes | 1 | 2014 | 146 | 0.110 |
Why?
| | Genes, p53 | 1 | 2013 | 50 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 1004 | 0.100 |
Why?
| | Middle Aged | 2 | 2025 | 13133 | 0.090 |
Why?
| | Disease Progression | 3 | 2020 | 870 | 0.090 |
Why?
| | Female | 3 | 2025 | 28277 | 0.090 |
Why?
| | Models, Statistical | 1 | 2012 | 230 | 0.090 |
Why?
| | Aged | 1 | 2025 | 10242 | 0.090 |
Why?
| | Plant Roots | 2 | 2022 | 26 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2023 | 211 | 0.080 |
Why?
| | Bacteria | 2 | 2021 | 223 | 0.080 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 2 | 2019 | 14 | 0.070 |
Why?
| | Inflammation | 2 | 2023 | 649 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1216 | 0.070 |
Why?
| | Histone-Lysine N-Methyltransferase | 2 | 2019 | 56 | 0.070 |
Why?
| | Animals | 5 | 2021 | 13485 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2020 | 1483 | 0.050 |
Why?
| | Phonation | 1 | 2023 | 15 | 0.050 |
Why?
| | Platelet Aggregation | 1 | 2023 | 76 | 0.050 |
Why?
| | Albuminuria | 1 | 2022 | 47 | 0.050 |
Why?
| | Adenosine | 1 | 2023 | 75 | 0.050 |
Why?
| | Neoplasms | 1 | 2012 | 1314 | 0.050 |
Why?
| | Ticlopidine | 1 | 2023 | 71 | 0.050 |
Why?
| | Models, Animal | 1 | 2021 | 230 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 390 | 0.040 |
Why?
| | Blood Urea Nitrogen | 1 | 2020 | 40 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2021 | 355 | 0.040 |
Why?
| | Swine | 1 | 2021 | 428 | 0.040 |
Why?
| | Milk, Human | 1 | 2021 | 122 | 0.040 |
Why?
| | Cytokines | 1 | 2022 | 622 | 0.040 |
Why?
| | RNA, Plant | 1 | 2019 | 6 | 0.040 |
Why?
| | Databases, Protein | 1 | 2019 | 29 | 0.040 |
Why?
| | Genes, Plant | 1 | 2019 | 10 | 0.040 |
Why?
| | Symbiosis | 1 | 2019 | 12 | 0.040 |
Why?
| | Mice | 2 | 2020 | 5899 | 0.040 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2019 | 45 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 146 | 0.040 |
Why?
| | Motor Neurons | 1 | 2018 | 36 | 0.040 |
Why?
| | Neuroglia | 1 | 2018 | 39 | 0.040 |
Why?
| | Spinal Cord | 1 | 2018 | 169 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 127 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 566 | 0.030 |
Why?
| | Data Mining | 1 | 2017 | 44 | 0.030 |
Why?
| | Models, Biological | 1 | 2019 | 735 | 0.030 |
Why?
| | Phosphorylation | 1 | 2017 | 536 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2019 | 1558 | 0.030 |
Why?
| | Genomics | 1 | 2017 | 266 | 0.030 |
Why?
| | DNA Repair | 1 | 2016 | 194 | 0.030 |
Why?
| | Cell Line | 1 | 2017 | 1020 | 0.030 |
Why?
| | Mutation | 1 | 2019 | 1331 | 0.030 |
Why?
| | Rats | 1 | 2019 | 3228 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 5508 | 0.020 |
Why?
| | Infant | 1 | 2016 | 3709 | 0.020 |
Why?
|
|
Rahmatallah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|